SHAREHOLDER ALERT: Cibus, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
10 juin 2024 11h16 HE
|
Block & Leviton LLP
Cibus, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm.
Cibus Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
04 juin 2024 12h27 HE
|
Block & Leviton LLP
Cibus, Inc. investigated for potential securities law violations. Investors who have lost money in their Cibus investment should contact Block & Leviton.
SHAREHOLDER ALERT: Fastly Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses
03 juin 2024 09h38 HE
|
Block & Leviton LLP
A securities fraud lawsuit has been filed against Fastly (FSLY). Investors who have lost money in their Fastly investment should contact Block & Leviton.
Fastly Sued For Securities Violations; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
28 mai 2024 19h21 HE
|
Block & Leviton LLP
Block & Leviton announces a securities fraud lawsuit has been filed against Fastly (NYSE: FSLY). Investors who have lost money should contact the firm.
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
08 mai 2024 07h00 HE
|
Cingulate Inc.
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
30 avr. 2024 05h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
01 avr. 2024 08h00 HE
|
Cingulate Inc.
$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) --...
Cingulate to Attend DCAT Week 2024 in New York City
06 mars 2024 06h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13 févr. 2024 06h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $7.5 Million Public Offering
06 févr. 2024 16h15 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...